Pharmaceutical Chemistry Journal

, Volume 52, Issue 1, pp 15–18 | Cite as

Sustained-Release Tablets of Hydrochlorothiazide, a Slightly Water-Soluble Molecule Using Glyceryl Behenate

  • S. I. Chemsa
  • A. Maïza
  • P. Arnaud

Hydrochlorothiazide (Hctz) is an antihypertensive drug acting as diuretic. In order to prolong the drug activity, various formulations of Hctz were developed. This work was aimed at developing a sustained-release formulation using glyceryl behenate (Compritol 888 ATO, C888) as a waxy retardant matrix and Hctz as the model of slightly water-soluble drug. Two different ratios of Hctz/C888 (1:1 and 1:2) were tried to determine if increasing the C888 fraction will retard the release of Hctz. Melt granulation and direct compression have been tested on the two ratios in order to identify which one is most effective to modify the release of Hctz. The results showed that the 1:2 ratio (Hctz 25 mg versus C888 50 mg) successfully retarded the dissolution of Hctz. On the other hand, hot fusion method was found to be more effective than compression of physical mixtures in retarding the drug dissolution from the matrix. Thus, formulations based on the appropriate matrix of Compritol 888 ATO can be used to produce prolonged-release tablets for slightly water-soluble drugs like Hctz.


hydrochlorothiazide glyceryl behenate Compritol 888 ATO sustained release tablets drug dissolution profile 



The authors are grateful to Laboratoire Salem and would also like to thank University Paris Descartes, Faculty of Pharmacy for their cooperation.

Declaration of Interests

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.


  1. 1.
    D. A. Sica and A. C. Schoolwerth, Renal Handing of Organic Anions and Cations and Renal Excretion of Uric Acid, in: The Kidney, B. Brenner and F. Rector (eds.), W. B. Saunders, Philadelphia (2004), pp. 637 – 662.Google Scholar
  2. 2.
    E. J. Weinman, G. Eknoyan, and W. N. Suki, J. Clin. Invest, 55, 283 – 291 (1975).CrossRefGoogle Scholar
  3. 3.
    D. C. Brater and J. R. Voelker, Use of diuretics in patients with renal disease, in: Contemporary Issues of Nephrology. Pharmacotherapy of Renal Disease and Hypertension, W. M. Bennett and D. A. McCarron (eds.), Churchill Livingstone, New York (1987), Vol. 17, pp. 115 – 147.Google Scholar
  4. 4.
    H. Knauf, J. Cardiovasc. Pharmacol., 22(6), S1-S7 (1993).CrossRefPubMedGoogle Scholar
  5. 5.
    P. Barthelemy, J. P. Laforet, N. Farah, et al., Eur. J. Pharm. Biopharm., 47(1), 87 – 90 (1999).CrossRefPubMedGoogle Scholar
  6. 6.
    D. Bidah and J. M. Vergnaud, Int. J. Pharm., 77, 81 – 87 (1991).CrossRefGoogle Scholar
  7. 7.
    J. Swarbrick and J. C. Boylan, Encyclopedia of Pharmaceutical Technology, Marcel Dekker, New York (1994), pp. 165 – 190.Google Scholar
  8. 8.
    M. K. Darwish, M. M. Fouad, H. E. Zaazaa, et al., J. Global Trends Pharm. Sci., 5(3), 1756 – 1768 (2014).Google Scholar
  9. 9.
    W. Sutanata, D. Q. M. Craig, and J. M. Newton, J. Pharm. Pharmacol., 47, 182 – 187 (1995).CrossRefGoogle Scholar
  10. 10.
    P. Costa and J. M. S. Lobo, Eur. J. Pharm. Sci., 13, 123 – 133 (2001).CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Faculty of Technology, F. Abbas University, Process Engineering DepartmentSetifAlgeria
  2. 2.Laboratoires SalemEl EulmaAlgeria
  3. 3.Faculty of PharmacyUniversity Paris DescartesParisFrance

Personalised recommendations